Form 4: Mirum Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Mirum Pharmaceuticals CEO, Christopher Peetz, sold 7,489 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Christopher Peetz, CEO of Mirum Pharmaceuticals, sold 7,489 shares of common stock on January 7, 2025.
• The sale was executed at a price of $42.8153 per share.
• The transaction was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Mr. Peetz directly owns 119,359 shares and indirectly owns 208,570 shares through The Peetz Family Trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment regarding the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 7,489 shares is not unusual for a CEO of a company of this size.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Mirum Pharmaceuticals, Christopher Peetz, stock sale, Form 4, insider trading, tax obligations, restricted stock units